Stran Loyalty Solutions, which serves casino and gaming customers, liftedGross Profit92.4% to USD 3.0 million from USD 1.6 million. Management said the segment generated about USD 687,000 ofOperating Incomeagainst a prior loss, which matches the calculated gap between USD 3.0 million of gross profit …
Swarmer signed a definitive agreement on September 9, 2026 to acquire Ratel Robotics, a Ukrainian maker of unmanned ground vehicles, and shareholders approved the share issuance on November 2. Management expects closing in November. Ratel's preliminary unaudited revenue was USD 42.1 million for nine …
Income from operations grew to USD 4,811 million from USD 4,165 million, but net interest expense rose to USD 2,008 million from USD 1,572 million, so net income barely moved. Net income applicable to common stockholders was USD 2,048 million after USD 59 million …
Total operating expenses excluding other expenses fell 17.8% to USD 17.6 million from USD 21.4 million, and loss from operations was USD 7.3 million, a USD 0.3 million improvement. Management attributed the gains to a September realignment that included a headcount reduction of about …
Gross profit increased 13.6% to USD 11.55 million, and gross margin rose to 62.4% from 58.9%. The filing says tariff refunds received in the quarter represented about 270 of the 350 basis points of improvement, so roughly 80 basis points came from sales growth …
Key HighlightsThird-quarterRevenuewas USD 12.9 million, up about 11% from USD 11.6 million a year earlier and up about 13% from USD 11.4 million in the second quarter, though management said growth was below its own expectation.Full-year 2026 revenue guidance was updated to USD 46 …
Key HighlightsThird-quarterRevenuewas USD 13.1 million versus USD 15.0 million in the second quarter, a sequential decline of about 13% that management attributed to lower Gram prices, since the number of Gram earned stayed consistent.Operating income from continuing operations was USD 4.0 million against about …
Most of the increase went to oral dabogratinib, the lead program, which the company is advancing in three Phase 2 trials it calls its 3x3 strategy. External spending in the quarter was USD 7.3 million on SURF302 in bladder cancer, USD 5.9 million on …
Key HighlightsThird-quarter netRevenuewas USD 88.0 million, down 5.0% from USD 92.7 million, with the company citing weak radio conditions, lower cable scatter rates and large national digital client attrition.Net loss attributable to common stockholders was USD 119.2 million, or USD 26.39 per basic share, …
Cash, cash equivalents and short-term investments fell to USD 207.4 million, and total stockholders'Equitywas USD 234.0 million against USD 339.8 million at December 31, 2025. The company has raised USD 670.9 million since inception, including USD 268.8 million of net IPO proceeds and USD …